Shares of Johnson & Johnson (NYSE:JNJ) ended Tuesday session in green amid volatile trading. The shares closed up +0.96 points or 0.84% at $114.68 with 8.36 million shares getting traded. Post opening the session at $114.00, the shares hit an intraday low of $113.92 and an intraday high of $115.00 and the price vacillated in this range throughout the day. The company has a market cap of $319.08 billion and the numbers of outstanding shares have been calculated to be 2.76 billion shares.
Johnson & Johnson (JNJ) on May 9, 2016 announced that it will participate in the 2016 UBS Global Healthcare Conference on Monday, May 23, at the Grand Hyatt New York. Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Company in a session scheduled at 9:00 a.m. (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately two hours after the live webcast.
Shares of Novavax, Inc. (NASDAQ:NVAX) ended Tuesday session in red amid volatile trading. The shares closed down -0.12 points or -2.51% at $4.67 with 6.26 million shares getting traded. Post opening the session at $4.80, the shares hit an intraday low of $4.49 and an intraday high of $4.90 and the price vacillated in this range throughout the day. The company has a market cap of $1.31 billion and the numbers of outstanding shares have been calculated to be 270.78 million shares.
Novavax, Inc. (NVAX) on May 04, 2016 announced its financial results for the first quarter ended March 31, 2016.
Financial Results for the Three Months Ended March 31, 2016
Novavax reported a net loss of $77.3 million, or $0.29 per share, for the first quarter of 2016, compared to a net loss of $24.4 million, or $0.10 per share, for the first quarter of 2015.
Novavax revenue in the first quarter of 2016 decreased 57% to $4.2 million, compared to $9.9 million for the same period in 2015. Lower revenue under the HHS BARDA contract of $7.3 million is the primary driver of this decrease. The lower HHS BARDA revenue is the result of a lower level of activity in the three months ended March 31, 2016, as compared to the same period in 2015, along with a one-time revenue recognition of $3.1 million in the first quarter of 2015. This decrease in HHS BARDA revenue was partially offset by $1.6 million in revenue recorded under the BMGF grant relating to our ongoing Prepare clinical trial.
Research and development expenses increased 143% to $69.0 million in the first quarter of 2016, compared to $28.3 million for the same period in 2015. The increase in research and development expenses was primarily due to increased costs associated with the clinical trials and development activities of our RSV F Vaccine and higher employee-related costs, including non-cash stock-based compensation.
Shares of Opko Health Inc. (NYSE:OPK) ended Tuesday session in green amid volatile trading. The shares closed up +0.11 points or 1.12% at $10.38 with 4.60 million shares getting traded. Post opening the session at $10.48, the shares hit an intraday low of $10.04 and an intraday high of $10.57 and the price vacillated in this range throughout the day. The company has a market cap of $5.97 billion and the numbers of outstanding shares have been calculated to be 547.44 million shares.
Opko Health Inc. (OPK) on 10 May, 2016 announced the appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access to support the anticipated launch of RAYALDEE®.
Mr. Nusbickel has over 25 years of pharmaceutical experience with established large companies, such as Hospira, Amgen and Abbott, with a career long focus on specialty products and nephrology. He has been involved in numerous product launches including serving as the global lead for Amgen’s launch of Sensipar, and has deep connections with managed care organizations and with key nephrology opinion leaders. Prior to joining OPKO, Mr. Nusbickel served as Hospira’s Head of U.S. Market Access, Biologics and as Amgen’s Executive Director, Value Access and Advocacy.
“OPKO is proud to add Tom to our growing management team responsible for commercializing RAYALDEE in the U.S. Tom has extensive, successful experience in launching new products in the U.S. chronic kidney disease market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, “and we are confident that he will help drive Rayaldee to great success.”